Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionATPase-coupled monoatomic cation transmembrane transporter activity

ATP13A3 ATP6V0A1

1.11e-0362162GO:0019829
GeneOntologyMolecularFunctionATPase-coupled transmembrane transporter activity

ATP13A3 ATP6V0A1

3.37e-03109162GO:0042626
Pubmed

Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.

SACS ADGRL1 DOCK9 ATP6V0A1

1.61e-0534716417114649
Pubmed

Mapping genes that control hormone-induced ovulation rate in mice.

GUSB CYP19A1

1.80e-051416210491617
Pubmed

RUNX1 maintains the identity of the fetal ovary through an interplay with FOXL2.

DMRT1 CYP19A1

4.15e-052116231712577
Pubmed

TRIM28-dependent SUMOylation protects the adult ovary from activation of the testicular pathway.

DMRT1 CYP19A1

4.56e-052216235906245
Pubmed

Female-to-male sex reversal in mice caused by transgenic overexpression of Dmrt1.

DMRT1 CYP19A1

9.76e-053216225725066
Pubmed

Foxl2 functions in sex determination and histogenesis throughout mouse ovary development.

DMRT1 CYP19A1

2.90e-045516219538736
Pubmed

Proteomics strategy to identify substrates of LNX, a PDZ domain-containing E3 ubiquitin ligase.

VRK2 DOCK9

3.46e-046016222889411
InteractionCYP19A1 interactions

VRK2 CYP19A1 ATP13A3

6.10e-0646163int:CYP19A1
InteractionRHOJ interactions

ADGRL1 VRK2 DOCK9 ATP13A3 ATP6V0A1

9.86e-05633165int:RHOJ
InteractionRHOF interactions

ADGRL1 VRK2 DOCK9 ATP13A3 ATP6V0A1

1.32e-04673165int:RHOF
InteractionRAC2 interactions

ADGRL1 VRK2 DOCK9 ATP13A3 ATP6V0A1

1.32e-04674165int:RAC2
ToppCellFetal_29-31_weeks-Immune-dendritic_cell-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

TLR10 PLXNA4 CYP19A1

1.97e-0515016357f21ad380fd1350a2c25d75ad8c3b763ded53ec
ToppCellLAM-Lymphoid-pDC|LAM / Condition, Lineage and Cell class

TLR10 PLXNA4 GRIA3

2.43e-05161163bb5b44713e4da4406cdaa79dcf2aa9f97e3cf75a
ToppCell5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-tracheobronchial_smooth_muscle_cell-Fibromyocytes-Fibromyocytes_L.2.3.2.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

PLXNA4 SACS GRIA3

3.62e-051841637b5678718719020b52e7c2a7bd9797987defd7ff
ToppCell5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-tracheobronchial_smooth_muscle_cell-Fibromyocytes|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

PLXNA4 SACS GRIA3

3.62e-0518416354e5b63f55b8d6eccad53d389ea9c78f991e1414
ToppCelldroplet-Marrow-BM-1m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GRIA3 GUSB VRK2

3.80e-05187163028e7d6e1211e123879d2f353dc32fae1185dd8e
ToppCellfacs-Marrow-KLS-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GRIA3 GUSB VRK2

3.92e-05189163b28a0e2d5a5f512f9b137b162b195bdc3d5ee9ba
ToppCellfacs-Brain_Non-Myeloid-Cortex-24m-Neuronal|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLXNA4 ADGRL1 GRIA3

4.18e-05193163be28070c049e7cb68bcd54f582226eb2f5e4bc1c
ToppCellfacs-Brain_Non-Myeloid-Cortex-24m-Neuronal-nan|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLXNA4 ADGRL1 GRIA3

4.18e-051931630c652ebe22ce5d2927599dd97ef1920547858395
ToppCellfacs-Brain_Non-Myeloid-Cortex-24m-Neuronal-neuron|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLXNA4 ADGRL1 GRIA3

4.18e-051931638689a70a33a7c3823dc647d41ac0160e7c3ae396
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

PLXNA4 DOCK9 ATP13A3

4.18e-051931630b328f725f6feba263783eaca60c142e80df90f3
Drug17a-methyltestosterone

DMRT1 GUSB CYP19A1

6.49e-0725163CID000004160
DrugAC1Q6XHZ

GUSB CYP19A1

1.39e-063162CID000119207
Drugantineutrophil cytoplasmic antibody

SACS ADGRL1 GUSB

6.16e-0652163CID000002201
DrugRMI 12,936

GUSB CYP19A1

1.29e-058162CID000039832
Drug4-hydroxy-N-demethyltamoxifen

GUSB CYP19A1

1.29e-058162CID003035980
Drugphthalamic acid

GUSB CYP19A1

1.66e-059162CID000006957
Drugestriol glucuronide

GUSB CYP19A1

2.08e-0510162CID000152963
DrugO-desmethylangolensin

GUSB CYP19A1

3.04e-0512162CID000089472
Drug4'-hydroxyflavanone

GUSB CYP19A1

3.60e-0513162CID000165506
Drughypoxoside

GUSB CYP19A1

4.84e-0515162CID006438448
DrugAC1L1O7J

GUSB CYP19A1 ATP6V0A1

4.97e-05104163CID000007189
Drugrooperol

GUSB CYP19A1

5.52e-0516162CID006438989
DrugG-F-P

DMRT1 GUSB CYP19A1

5.71e-05109163CID000449515
Drugenterodiol

GUSB CYP19A1

7.86e-0519162CID000115089
Drugtrenbolone

GUSB CYP19A1

8.73e-0520162CID000025015
Drughyoscine-N-butylbromide

ADGRL1 GUSB

8.73e-0520162CID000003636
Drug3,4-dioctylphthalic acid

GRIA3 GUSB CYP19A1

8.79e-05126163CID005743034
DrugAC1L1HD4

GUSB CYP19A1

9.65e-0521162CID000004079
Drugenterolactone

GUSB CYP19A1

1.06e-0422162CID000114739
DrugEx-PRESS

GUSB CYP19A1

1.16e-0423162CID000153909
DrugAC1L2K1Q

GUSB CYP19A1

1.16e-0423162CID000022258
Drug2,4,6-tribromophenol

ADGRL1 CYP19A1

1.38e-0425162CID000001483
Drug9-aminocamptothecin

ADGRL1 GUSB

1.86e-0429162CID000072402
DrugNSC117862

GUSB CYP19A1

1.99e-0430162CID000003648
Drugallopregnandiol

GUSB CYP19A1

1.99e-0430162CID000004901
DrugBP-7,8-oxide

GUSB CYP19A1

2.27e-0432162CID000037455
Drugnorbuprenorphine

GUSB CYP19A1

2.41e-0433162CID000114976
Drugdiazomethane

ADGRL1 GUSB

2.56e-0434162CID000009550
Drugpregnanetriol

GUSB CYP19A1

2.88e-0436162CID000101967
Drugglycitein

GUSB CYP19A1

2.88e-0436162CID005317750
DrugClonidine hydrochloride [4205-91-8]; Down 200; 15uM; MCF7; HT_HG-U133A

ADGRL1 DOCK9 ATP6V0A1

2.96e-041901633172_DN
Drug3-trimethylsilylpropionate

DMRT1 CYP19A1

3.04e-0437162CID000079764
DrugAlprenolol hydrochloride [13707-88-5]; Down 200; 14uM; MCF7; HT_HG-U133A

ATP13A3 HOXC5 ATP6V0A1

3.05e-041921633188_DN
DrugMethapyrilene hydrochloride [135-23-9]; Up 200; 13.4uM; PC3; HT_HG-U133A

DOCK9 HOXC5 ATP6V0A1

3.14e-041941636644_UP
DrugClotrimazole [23593-75-1]; Down 200; 11.6uM; MCF7; HT_HG-U133A

HOXC5 TUT7 ATP6V0A1

3.14e-041941633166_DN
DrugHydroflumethiazide [135-09-1]; Down 200; 12uM; MCF7; HT_HG-U133A

ADGRL1 DOCK9 SLC35F5

3.19e-041951631687_DN
DrugMebhydroline 1,5-naphtalenedisulfonate [6153-33-9]; Up 200; 4.8uM; MCF7; HT_HG-U133A

ADGRL1 DOCK9 ATP6V0A1

3.19e-041951633269_UP
Drugalternariol

GUSB CYP19A1

3.21e-0438162ctd:C005197
DrugAC1L9GHY

GUSB ATP6V0A1

3.21e-0438162CID000444538
DrugMoxisylyte hydrochoride [964-52-3]; Up 200; 12.6uM; MCF7; HT_HG-U133A

DMRT1 ADGRL1 DOCK9

3.24e-041961637015_UP
DrugClofilium tosylate [92953-10-1]; Down 200; 7.8uM; MCF7; HT_HG-U133A

DOCK9 HOXC5 ATP6V0A1

3.24e-041961633187_DN
DrugTerbutaline hemisulfate [23031-32-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A

DOCK9 HOXC5 ATP6V0A1

3.29e-041971633202_DN
DrugBupropion hydrochloride [31677-93-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A

ADGRL1 HOXC5 ATP6V0A1

3.29e-041971633180_DN
DrugCarbinoxamine maleate salt [3505-38-2]; Up 200; 9.8uM; PC3; HT_HG-U133A

ADGRL1 DOCK9 HOXC5

3.29e-041971637138_UP
DrugColistin sulfate [1264-72-8]; Up 200; 3uM; MCF7; HT_HG-U133A

DOCK9 HOXC5 ATP6V0A1

3.29e-041971634796_UP
DrugSulfacetamide sodic hydrate [6209-17-2]; Up 200; 15.8uM; MCF7; HT_HG-U133A

ADGRL1 HOXC5 ATP6V0A1

3.29e-041971631695_UP
Drugfelodipine; Up 200; 10uM; MCF7; HG-U133A

DOCK9 CYP19A1 HOXC5

3.29e-04197163337_UP
DrugFlumequine [42835-25-6]; Up 200; 15.4uM; MCF7; HT_HG-U133A

ADGRL1 DOCK9 ATP6V0A1

3.29e-041971635529_UP
DrugClemizole hydrochloride [1163-36-6]; Up 200; 11uM; PC3; HT_HG-U133A

GRIA3 DOCK9 ATP6V0A1

3.29e-041971633672_UP
DrugGliclazide [21187-98-4]; Down 200; 12.4uM; MCF7; HT_HG-U133A

ADGRL1 ATP13A3 TUT7

3.29e-041971632870_DN
DrugEpivincamine [6835-99-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A

ADGRL1 ATP13A3 ATP6V0A1

3.34e-041981636838_DN
DrugDisopyramide [3737-09-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A

DMRT1 ADGRL1 ATP6V0A1

3.34e-041981637035_UP
DrugAntipyrine [60-80-0]; Up 200; 21.2uM; PC3; HT_HG-U133A

CYP19A1 ATP6V0A1 SLC35F5

3.34e-041981634251_UP
DrugPepstatin A [26305-03-3]; Up 200; 5.8uM; MCF7; HT_HG-U133A

ADGRL1 ATP13A3 HOXC5

3.39e-041991633264_UP
Drugamitriptyline hydrochloride; Up 200; 1uM; MCF7; HG-U133A

ADGRL1 VRK2 ATP13A3

3.39e-04199163167_UP
DrugLeucomisine [17946-87-1]; Up 200; 16.2uM; HL60; HT_HG-U133A

GRIA3 DOCK9 CYP19A1

3.39e-041991636125_UP
Drugdexamethasone; Down 200; 1uM; MCF7; HG-U133A

ADGRL1 VRK2 ATP13A3

3.39e-04199163123_DN
DrugPrednisolone [50-24-8]; Up 200; 11uM; MCF7; HT_HG-U133A

DOCK9 HOXC5 ATP6V0A1

3.39e-041991635526_UP
DrugCiprofloxacin hydrochloride [93107-08-5]; Up 200; 10.8uM; PC3; HT_HG-U133A

GRIA3 ATP6V0A1 SLC35F5

3.39e-041991636700_UP
DrugCephalosporanic acid, 7-amino [957-68-6]; Up 200; 14.6uM; PC3; HT_HG-U133A

DMRT1 CYP19A1 ATP6V0A1

3.44e-042001634242_UP
DrugCitalopram

GRIA3 CYP19A1

3.56e-0440162ctd:D015283
DrugAC1NS0BY

GUSB CYP19A1

3.56e-0440162CID005326325
DrugTrimethylsilyl

GUSB CYP19A1

3.56e-0440162CID000123362
Drugp-Nitrophenyl alpha-D-xyloside

ADGRL1 GUSB

3.74e-0441162CID000082482
DrugAC1L1IMA

GUSB CYP19A1

3.74e-0441162CID000004639
Drugtestosterone glucuronide

GUSB CYP19A1

3.74e-0441162CID000108192
Drugpamidronate

GUSB CYP19A1

5.34e-0449162CID000004673
DrugAC1LD7MJ

GUSB CYP19A1

5.34e-0449162CID000643628
Drugp,p'-hydroxy-DDT

GUSB CYP19A1

5.56e-0450162CID000076302
Drug9-hydroxybenzo(a)pyrene

GUSB CYP19A1

6.25e-0453162CID000028598
DrugSureCN5628906

DMRT1 CYP19A1

6.49e-0454162CID010476254
Drug4-tert-octylphenol

GUSB CYP19A1

6.49e-0454162CID000008814
Drugtamibarotene

SACS VRK2 ATP13A3 ATP6V0A1

6.58e-04596164ctd:C061133
DrugAC1L4WZL

GUSB CYP19A1

6.73e-0455162CID000165628
Drugisoxazole

GRIA3 CYP19A1

6.97e-0456162CID000009254
Diseasesusceptibility to chronic sinus infection measurement

PLXNA4 CYP19A1

6.15e-0468162EFO_0008419
Diseasebone fracture

PLXNA4 CYP19A1

1.65e-03112162EFO_0003931
Diseasefemoral neck bone mineral density

PLXNA4 DMRT1

4.95e-03196162EFO_0007785
Diseasesmoking behaviour measurement

PLXNA4 VRK2

6.31e-03222162EFO_0005671

Protein segments in the cluster

PeptideGeneStartEntry
PFRQPCYKNYFFVFS

ATP13A3

1096

Q9H7F0
TFPNPYQFISSVDYN

ADGRL1

361

O94910
ANSFYKQSPNIPAYN

HOXC5

6

Q00444
FKPAPATNTQNYATY

GRIA3

866

P42263
LNKTNFTYYPNPVFE

PLXNA4

1131

Q9HCM2
FPNYVNSSYIPTKQF

DOCK9

596

Q9BZ29
ENFAKNVPYRYFQPF

CYP19A1

416

P11511
PKGYFVQNTYFDFFN

GUSB

196

P08236
QTYSQRFFVPPTFKS

SACS

4426

Q9NZJ4
SSFYQPSLFPYYNNL

DMRT1

211

Q9Y5R6
SYVFTQYNKPFFSTF

SLC35F5

91

Q8WV83
MLFPNYPTKFQYLNF

TLR10

341

Q9BXR5
NTQKVTCFYQPAPYF

TENT5D

341

Q8NEK8
PPTYNKTNKFTYGFQ

ATP6V0A1

361

Q93050
AVSSNPYAFKNPIYS

TUT7

71

Q5VYS8
FPQKISYTQFPNSFY

VRK2

416

Q86Y07